Details

Autor(en) / Beteiligte

• Moreira, Edson D.
• Kitchin, Nicholas
• Xu, Xia
• Dychter, Samuel S.
• Lockhart, Stephen
• Gurtman, Alejandra
• Perez, John L.
• Zerbini, Cristiano
• Dever, Michael E.
• Jennings, Timothy W.
• Brandon, Donald M.
• Cannon, Kevin D.
• Koren, Michael J.
• Denham, Douglas S.
• Berhe, Mezgebe
• Fitz-Patrick, David
• Hammitt, Laura L.
• Klein, Nicola P.
• Nell, Haylene
• Keep, Georgina
• Wang, Xingbin
• Koury, Kenneth
• Swanson, Kena A.
• Cooper, David
• Lu, Claire
• Türeci, Özlem
• Lagkadinou, Eleni
• Tresnan, Dina B.
• Dormitzer, Philip R.
• Şahin, Uğur
• Gruber, William C.
• Jansen, Kathrin U.

Titel

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Ist Teil von

• The New England journal of medicine, 2022-05, Vol.386 (20), p.1910-1921

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• In an extension of the pivotal randomized trial showing vaccine efficacy, approximately 10,000 adults who had received two doses of BNT162b2 were assigned to receive a third dose or placebo. Local reactions were common but mild and transient. During a median follow-up of 2.5 months, SARS-CoV-2 was identified in 6 participants in the vaccine group and in 123 in the placebo group, for a vaccine efficacy of 95.3%.